What is Hunter syndrome?

Hunter syndrome, also known as mucopolysaccharidosis II (MPS II) is a rare, progressive genetic disorder. It predominantly affects males, occurring in approximately 1 in 162,000 live births.1

Hunter syndrome is one of a number of lysosomal storage diseases (LSDs), in which molecules build up in the body. In Hunter syndrome specifically, glycosaminoglycans (GAGs) accumulate abnormally in the body.2

Hunter syndrome is caused by a deficiency or absence of the I2S enzyme.3 Without I2S, GAGs accumulate in the lysosomes, and in Hunter syndrome patients, the progressive build-up interferes with cell functions across all organ systems. The multisystemic disease is associated with many signs and symptoms, which lie on a spectrum from non-neuronopathic (somatic) symptoms to neuronopathic (cognitive) symptoms. Almost 7 out of 10 patients with Hunter syndrome have neuronopathic involvement.3,4

Initial signs of GAG accumulation in Hunter syndrome patients occur from ages 2 to 4 years: hernia, otitis media, and enlarged adenoids/tonsils (managed by adenoidectomy/tonsillectomy). The clinical management of Hunter syndrome patients is continual, symptoms are progressive and multisystemic, and the median life expectancy for patients is 13.4 years.3,5,6

Hunter syndrome presentation

The presentation of Hunter syndrome symptoms is unique in each patient and there is no typical disease course. However, the early symptoms overlap with common childhood complaints, making it challenging to detect and ultimately leading to diagnostic delays.5 It is important therefore to be able to recognise clusters of symptoms that may indicate an underlying problem:

Many of the signs and symptoms of [MPS II] overlap with common paediatric problems…it’s not coincidental that a patient has three or four or five different medical issues.

- Dr Barbara Burton

Hunter syndrome inheritance

Hunter syndrome is an X-linked recessive genetic disorder, occurring almost exclusively in males. The disease arises from the lack of a normal copy of the IDS gene on the X chromosome, which codes for the lysosomal enzyme iduronate-2-sulfatase (I2S) that clears GAGs.5

It is extremely rare for females to develop Hunter syndrome; heterozygous females retain 50% of their normal I2S activity, and are usually asymptomatic.7

The IDS gene contains a little over 28,000 DNA base pairs, and more than 500 different mutations that lead to Hunter syndrome have been documented, including point mutations, splicing defects, gene rearrangements, and even complete deletions.8,9

Depending on the scope and size of the mutation, there will be an abnormality, or a complete absence of I2S. Such mutations lead to Hunter syndrome conditions of differing severity and course; the presentation cannot be predicted from the mutation type, although large gene rearrangements usually create neuronopathic symptoms.9

It is essential to check family members of the Hunter syndrome patient for faulty copies of the IDS gene. Genetic testing will identify carriers and undiagnosed children who may be affected. Early management is essential in a progressive disease.3

Register for exclusive content

The contact information collected in this form will be used to subscribe you to receive electronic communication via email. *

You have the right to opt out of receiving electronic communications at any time by using the opt out link in the communication or by contacting us at privacyconnect@takeda.com

For more information on how Takeda processes your personal data, please refer to our Privacy Notice